VOYAGER THERAPEUTICS INC

VYGRNASDAQ

🏆 #3027 by market capEarnings Nov 9US Equity

$3.20▲ $0.03 (+0.95%)

🌙 After hours$3.25▲ 1.61%Regular close · extended-hours price shown

1h—

24h▲ 0.9%

7d▲ 3.9%

14d▲ 6.7%

30d▼ 1.5%

1y▼ 5.6%

🏦Market Cap

$193M

Small Cap

📈Revenue Growth (YoY)

-19.1%

Declining

📊Gross Margin

—

💵FCF Margin

164.3%

Strong

⚖️P/S Ratio

5.7x

Fair

Otter Score

Weak

Trading Snapshot

Day Range: $3.18 – $3.24
52-Week Range: $2.94 – $5.55
Volume: $2.65B
Avg Volume: $2.15B
Shares Outstanding: 60.4M
Next Earnings: Oct 3, 2026

Fundamentals Snapshot

Annual Revenue: $40M
Last Q Revenue: $3M
P/E Ratio: —
P/S Ratio: 5.7x
EPS (TTM): $-1.81
Dividend Yield: —

Why Investors Own VYGR

✓High-growth profile — revenue up +45.0% YoY with expanding US Equity exposure.
✓Healthy economics — 66% gross margin and 5% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$40M▲ +38.9% YoY

Gross Margin (TTM)

65.7%▲ +4.1% YoY

Operating Income (TTM)

$13M▲ +38.9% YoY

Free Cash Flow (TTM)

$2M▲ +38.9% YoY

About VOYAGER THERAPEUTICS INC

Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease. The company's preclinical portfolio is extensive, featuring VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. Additionally, Voyager is pursuing a Tau program aimed at various tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, alongside initiatives for spinal muscular atrophy. To advance its gene therapy product pipeline, the company has forged strategic collaboration and licensing agreements with key industry players such as Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. These partnerships cover the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and maintains its corporate headquarters in Cambridge, Massachusetts.

🦦